Cardiology

Surveillance and Genetics: Protecting Your Future and Family

At a Glance

LMNA-related cardiocutaneous progeria syndrome is monitored with personalized follow-up that may include heart-rhythm checks, echocardiograms, blood tests, cardiac MRI, and bone-density scans. Genetic counseling helps relatives understand testing and silent heart risks.

Living with LMNA-related cardiocutaneous progeria syndrome (LCPS) requires a shift in how you view medical care. It is no longer about “going to the doctor when you feel sick”; it is about proactive surveillance to catch changes before they become symptoms.

An Individualized Surveillance Plan

Because LCPS is ultra-rare, there is no single, fixed testing schedule that applies to every patient. Rather than a rigid roadmap, the frequency of your tests will depend on your specific LMNA variant, current symptoms, valve severity, ventricular function, and kidney health. Extrapolating from broader LMNA and lipodystrophy guidelines ^[1]^[2], your team will consider the following tools:

Clinical Exam: A thorough review of your heart sounds, skin changes, and fat distribution ^[3].
ECG and 24-hour Holter Monitor: To screen for silent “conduction disease” (like heart block) or brief runs of dangerous rhythms ^[4]^[5]. Frequency increases if you have a history of arrhythmias.
Echocardiogram: To track the progression of valve calcification and measure the heart’s pumping strength (LVEF) ^[3]^[6].
Metabolic Panel: Blood work for glucose, HbA1c, triglycerides, and liver enzymes to monitor for insulin resistance and fatty liver ^[7]^[1].
Cardiac MRI with late gadolinium enhancement (LGE): Used to look for fibrosis (scarring) in the heart muscle ^[8]^[9]. The use of MRI contrast depends on your kidney function, and the interval between scans is highly individualized.
Bone Density (DXA) Scan: To monitor for premature thinning of the bones ^[10].

The Critical Role of Family Screening

LCPS is a genetic condition, which means your family members may carry the same LMNA variant. Cascade testing is the process of testing your first-degree relatives (parents, siblings, and children) ^[11]^[5]. Importantly, this is generally only offered if your variant is confirmed to be “pathogenic” or “likely pathogenic”—it is not recommended for a “variant of uncertain significance” (VUS).

Silent Risk: In many families with LMNA mutations, relatives can be “genotype-positive” (they have the mutation) but “phenotype-negative” (they have no symptoms yet) ^[5].
The Danger of Waiting: Dangerous heart rhythms can occur in LMNA carriers even when the heart looks perfectly normal on an ultrasound ^[12]. In one study of a broad cohort of asymptomatic LMNA carriers, nearly 10% developed a newly documented cardiac phenotype each year ^[5].
Testing Children: Testing minors is a complex decision made with a genetic counselor and cardiologist. It is based on whether childhood screening will actively change their medical management or surveillance plan ^[13].

Managing the Psychological Toll

It is normal to feel a heavy psychological burden when living with a high risk of sudden cardiac death or the presence of an ICD.

Scan-xiety: The period leading up to your “check-up” can trigger significant anxiety ^[14]. Up to 47% of people with inherited heart conditions experience clinically significant anxiety ^[14].
ICD Distress: While the ICD is a life-saving “safety net,” it can also be a source of stress. Some patients experience hyper-vigilance or “shock anxiety”—the fear of the device firing unexpectedly ^[15]^[16].
ICD Action Plan: If you have an ICD and receive a single shock but feel fine, contact your clinic. If you receive multiple shocks or feel unwell, call emergency services immediately.
Supportive Interventions: Ask for a referral to a cardiac psychologist. They specialize in treating the psychological symptoms that can follow a cardiac event or a new diagnosis ^[17]^[18].

Note: Medical understanding of LCPS evolves rapidly; this information reflects current evidence, but recommendations may change as more LCPS-specific data develops.

Common questions in this guide

What heart and other tests are used to monitor LCPS?

Monitoring may include a clinical exam, an electrocardiogram, a 24-hour Holter monitor, an echocardiogram, blood tests for glucose, HbA1c, triglycerides, and liver enzymes, and sometimes cardiac MRI or a bone-density scan. The exact combination depends on the person’s LMNA variant, symptoms, heart function, valve disease, and kidney health.

How often should someone with LCPS have an ECG, Holter monitor, or echocardiogram?

There is no single testing schedule for everyone with LCPS. A cardiology team will set the timing based on the LMNA variant, symptoms, valve severity, heart-pumping function, kidney health, and any history of arrhythmias; monitoring may become more frequent when rhythm problems are present.

Can an LMNA carrier develop a dangerous heart rhythm without symptoms?

Yes. A person can carry an LMNA variant and have no noticeable symptoms or changes on an ultrasound while still being at risk for heart block or other dangerous rhythms. Planned heart-rhythm monitoring is important even when the heart appears normal.

Who should have cascade genetic testing for LCPS?

Cascade testing generally involves first-degree relatives, including parents, siblings, and children, when a pathogenic or likely pathogenic LMNA variant has been confirmed. It is generally not used to guide family testing for a variant of uncertain significance. Testing children should be considered with a genetic counselor and cardiologist when the result could change their care or screening.

What should I do if my ICD delivers a shock?

If you receive one ICD shock and feel well, contact your clinic for instructions. If you receive multiple shocks or feel unwell, call emergency services immediately. Your healthcare team can also help address anxiety after a shock.

How can I manage scan anxiety or distress about my ICD?

Scan anxiety, fear of an unexpected ICD shock, and constant monitoring of heart symptoms can be emotionally difficult. Ask your healthcare team about a referral to a cardiac psychologist, who can provide support for anxiety, hypervigilance, and stress related to inherited heart disease.

Get notified when new evidence is published on LMNA-related cardiocutaneous progeria syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (18)

1
A Novel Generalized Lipodystrophy-Associated Progeroid Syndrome Due to Recurrent Heterozygous LMNA p.T10I Mutation.
Hussain I, Patni N, Ueda M, et al.
The Journal of clinical endocrinology and metabolism 2018; (103(3)):1005-1014 doi:10.1210/jc.2017-02078.
PMID: 29267953
2
Looking at New Unexpected Disease Targets in LMNA-Linked Lipodystrophies in the Light of Complex Cardiovascular Phenotypes: Implications for Clinical Practice.
Mosbah H, Vatier C, Boccara F, et al.
Cells 2020; (9(3)) doi:10.3390/cells9030765.
PMID: 32245113
3
Increased ventilatory response to exercise in symptomatic and asymptomatic LMNA mutation carriers: a follow-up study.
Ollila L, Heliö T, Sovijärvi A, et al.
Clinical physiology and functional imaging 2017; (37(1)):8-16 doi:10.1111/cpf.12260.
PMID: 27966284
4
Timing of cardioverter-defibrillator implantation in patients with cardiac laminopathies-External validation of the LMNA-risk ventricular tachyarrhythmia calculator.
Rootwelt-Norberg C, Christensen AH, Skjølsvik ET, et al.
Heart rhythm 2023; (20(3)):423-429 doi:10.1016/j.hrthm.2022.11.024.
PMID: 36494026
5
Lamin A/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation.
Hasselberg NE, Haland TF, Saberniak J, et al.
European heart journal 2018; (39(10)):853-860 doi:10.1093/eurheartj/ehx596.
PMID: 29095976
6
Clinical Features of LMNA-Related Cardiomyopathy in 18 Patients and Characterization of Two Novel Variants.
Ferradini V, Cosma J, Romeo F, et al.
Journal of clinical medicine 2021; (10(21)) doi:10.3390/jcm10215075.
PMID: 34768595
7
Lipoatrophic diabetes in familial partial lipodystrophy type 2: From insulin resistance to diabetes.
Treiber G, Guilleux A, Huynh K, et al.
Diabetes & metabolism 2023; (49(2)):101409 doi:10.1016/j.diabet.2022.101409.
PMID: 36400409
8
Late gadolinium enhancement role in arrhythmic risk stratification of patients with LMNA cardiomyopathy: results from a long-term follow-up multicentre study.
Peretto G, Barison A, Forleo C, et al.
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2020; (22(12)):1864-1872 doi:10.1093/europace/euaa171.
PMID: 32995851
9
Can Circulating Cardiac Biomarkers Be Helpful in the Assessment of LMNA Mutation Carriers?
Chmielewski P, Michalak E, Kowalik I, et al.
Journal of clinical medicine 2020; (9(5)) doi:10.3390/jcm9051443.
PMID: 32408651
10
Recurrent Femoral Fractures in a Boy with an Atypical Progeroid Syndrome: A Case Report.
Jiajue R, Feng K, Wang R, Xia W
Calcified tissue international 2020; (106(3)):325-330 doi:10.1007/s00223-019-00639-5.
PMID: 31807803
11
Bridging the Gap Between Genetic Cardiomyopathies and Pregnancy.
Flores Rosario K, Hussien M, Grover P, et al.
JACC. Advances 2026; (5(6 Pt 1)):102784 doi:10.1016/j.jacadv.2026.102784.
PMID: 42132713
12
Cardiac and Neuromuscular Features of Patients With LMNA-Related Cardiomyopathy.
Peretto G, Di Resta C, Perversi J, et al.
Annals of internal medicine 2019; (171(7)):458-463 doi:10.7326/M18-2768.
PMID: 31476771
13
Extensive cardiac involvement in laminopathies diagnosed in pediatric-aged patients: A single-center study.
Hayes EA, Foreman K, Wright LK, et al.
Heart rhythm 2025; (22(12)):3308-3313 doi:10.1016/j.hrthm.2025.01.034.
PMID: 39894135
14
Are disease-specific patient-reported outcomes measures (PROMs) used in cardiogenetics? A systematic review.
van Pottelberghe S, Kupper N, Scheirlynck E, et al.
European journal of human genetics : EJHG 2024; (32(6)):607-618 doi:10.1038/s41431-023-01510-w.
PMID: 38097768
15
Psychosocial Implications of Living with Catecholaminergic Polymorphic Ventricular Tachycardia in Adulthood.
Richardson E, Spinks C, Davis A, et al.
Journal of genetic counseling 2018; (27(3)):549-557 doi:10.1007/s10897-017-0152-1.
PMID: 28940060
16
Information provision and follow-up of French patients with implantable cardioverter-defibrillators: The APODEC survey.
Halin A, Hamelin JL, Defaye P, et al.
Archives of cardiovascular diseases 2023; (116(12)):572-579 doi:10.1016/j.acvd.2023.10.005.
PMID: 37953189
17
Interdisciplinary psychosocial care for families with inherited cardiovascular diseases.
Caleshu C, Kasparian NA, Edwards KS, et al.
Trends in cardiovascular medicine 2016; (26(7)):647-53.
PMID: 27256036
18
Prevalence and predictors of adjustment disorder in patients with an implantable cardioverter-defibrillator.
Sila R, von Känel R, Attanasio V, et al.
Journal of psychosomatic research 2026; (209()):112866 doi:10.1016/j.jpsychores.2026.112866.
PMID: 42217314

This LCPS surveillance and genetics information is for educational purposes only and does not constitute medical advice; discuss testing schedules, family screening, and ICD concerns with your cardiologist and genetic counselor.

Guide Contents